Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Net Loans Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Dividends Paid - Common Dividends Paid - Common Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Preferred Shares Issued Preferred Shares Repurchased Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Fortress Biotech (FBIO) Change in Acquisitions & Divestments (2017 - 2019)

Fortress Biotech has reported Change in Acquisitions & Divestments over the past 3 years, most recently at $5.0 million for Q4 2019.

Quarterly results put Change in Acquisitions & Divestments at $5.0 million for Q4 2019, down 50.0% from a year ago — trailing twelve months through Dec 2020 was $5.0 million (down 77.88% YoY), and the annual figure for FY2019 was $22.6 million, down 68.16%.
Change in Acquisitions & Divestments for Q4 2019 was $5.0 million at Fortress Biotech, down from $5.0 million in the prior quarter.
Over the last five years, Change in Acquisitions & Divestments for FBIO hit a ceiling of $25.0 million in Q3 2018 and a floor of $5.0 million in Q4 2019.
Median Change in Acquisitions & Divestments over the past 3 years was $12.3 million (2018), compared with a mean of $14.2 million.
Peak annual rise in Change in Acquisitions & Divestments hit 47.67% in 2019, while the deepest fall reached 57.97% in 2019.
Fortress Biotech's Change in Acquisitions & Divestments stood at $20.1 million in 2017, then crashed by 50.22% to $10.0 million in 2018, then crashed by 50.0% to $5.0 million in 2019.
The last three reported values for Change in Acquisitions & Divestments were $5.0 million (Q4 2019), $5.0 million (Q2 2019), and $12.6 million (Q1 2019) per Business Quant data.